Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Bejar

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Hemasphere|May 22, 2024
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)Fabio Efficace, Rena Buckstein, Gregory A Abel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 5, 2015
Myelodysplastic syndromes, version 2.2015Peter L Greenberg, Richard M Stone, Rafael Bejar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyPeter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
Blood|April 30, 2020
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDSLuca Malcovati, Kristen Stevenson, Elli Papaemmanuil, et al.
Nature Communications|April 11, 2025
Natural killer cells' functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromesJuan Jose Rodriguez-Sevilla, Irene Ganan-Gomez, Bijender Kumar, et al.
Blood|September 21, 2022
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemiaEric J Duncavage, Adam Bagg, Robert P Hasserjian, et al.
Blood Reviews|March 18, 2023
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1<sup>st</sup> International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2026
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic LeukemiaLuca Lanino, Anthony M Hunter, Nico Gagelmann, et al.
Leukemia|January 13, 2019
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroupsDetlef Haase, Kristen E Stevenson, Donna Neuberg, et al.
Leukemia|October 20, 2022
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic SyndromesAmer M Zeidan, Jan Philipp Bewersdorf, Rena Buckstein, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Hemasphere|May 22, 2024
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)Fabio Efficace, Rena Buckstein, Gregory A Abel, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 5, 2015
Myelodysplastic syndromes, version 2.2015Peter L Greenberg, Richard M Stone, Rafael Bejar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 2, 2017
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyPeter L Greenberg, Richard M Stone, Aref Al-Kali, et al.
Blood|April 30, 2020
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDSLuca Malcovati, Kristen Stevenson, Elli Papaemmanuil, et al.
Nature Communications|April 11, 2025
Natural killer cells' functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromesJuan Jose Rodriguez-Sevilla, Irene Ganan-Gomez, Bijender Kumar, et al.
Blood|September 21, 2022
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemiaEric J Duncavage, Adam Bagg, Robert P Hasserjian, et al.
Blood Reviews|March 18, 2023
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1<sup>st</sup> International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2026
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic LeukemiaLuca Lanino, Anthony M Hunter, Nico Gagelmann, et al.
Leukemia|January 13, 2019
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroupsDetlef Haase, Kristen E Stevenson, Donna Neuberg, et al.
Leukemia|October 20, 2022
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic SyndromesAmer M Zeidan, Jan Philipp Bewersdorf, Rena Buckstein, et al.
Pageof 11